Multinationals Return To Growth In China In First Half
AZ and Novo Nordisk reported sales growth from innovative new drugs in China, despite the lingering impact of the country's volume-based procurement scheme. Meanwhile, Novartis, Sanofi and Roche saw gains for new antibody and cancer drugs, along with solid vaccine sales.